GRAL Stock Overview
A biotechnology company, focuses on developing technologies for early cancer detection.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
GRAIL, LLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.96 |
| 52 Week High | US$23.36 |
| 52 Week Low | US$12.51 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 9.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| GRAL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -19.7% | -1.9% | 0.5% |
| 1Y | n/a | 10.4% | 20.5% |
Return vs Industry: Insufficient data to determine how GRAL performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how GRAL performed against the US Market.
Price Volatility
| GRAL volatility | |
|---|---|
| GRAL Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: GRAL's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine GRAL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,360 | Bob Ragusa | grail.com |
GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests.
GRAIL, LLC Fundamentals Summary
| GRAL fundamental statistics | |
|---|---|
| Market cap | US$407.96m |
| Earnings (TTM) | -US$1.49b |
| Revenue (TTM) | US$100.18m |
4.0x
P/S Ratio-0.3x
P/E RatioIs GRAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRAL income statement (TTM) | |
|---|---|
| Revenue | US$100.18m |
| Cost of Revenue | US$192.09m |
| Gross Profit | -US$91.91m |
| Other Expenses | US$1.40b |
| Earnings | -US$1.49b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -56.17 |
| Gross Margin | -91.74% |
| Net Profit Margin | -1,488.21% |
| Debt/Equity Ratio | 0% |
How did GRAL perform over the long term?
See historical performance and comparison